FDA Advisory Committee to Weigh BPC-157, TB-500, MOTS-c, KPV, Semax & Epitalon for the 503A Compounding List

The FDA’s Pharmacy Compounding Advisory Committee (PCAC) meets July 23–24, 2026 to review a slate of peptides that have become fixtures of the wellness and longevity market — and to advise the agency on whether they belong on the 503A Bulks List, the roster of substances that compounding pharmacies are permitted to use. For a category that has spent years in regulatory gray zones, this is the most consequential peptide meeting in recent memory.

Here is what is actually on the agenda, what a listing would and would not mean, and why the outcome matters — without the hype.

TL;DR

• What: A two-day PCAC meeting to discuss seven bulk drug substances nominated for the Section 503A Bulks List.
• When & where: July 23–24, 2026, at FDA’s White Oak Campus in Silver Spring, MD, with a public online option.
• Which compounds: BPC-157, KPV, TB-500 and MOTS-c on Day 1; DSIP (Emideltide), Semax and Epitalon on Day 2.
• The stakes: A 503A listing would give traditional compounding pharmacies a clearer legal basis to compound these peptides for patient-specific prescriptions.
• The caveat: PCAC only makes non-binding recommendations. A committee vote is not a final FDA decision, and “not recommended” is not the same as “banned.”

What is PCAC, and what is the 503A Bulks List?

Advisory committees give the FDA independent expert input on scientific questions. Per the FDA, they “make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so.” In other words, PCAC advises; the agency decides.

The 503A Bulks List matters because of how U.S. compounding law works. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a traditional (503A) compounding pharmacy may compound a drug from a bulk substance only if that substance meets one of a few criteria — including appearing on FDA’s list of bulk drug substances that may be used in compounding. A substance that lands on the 503A Bulks List has a clear, affirmative legal pathway. A substance that does not remains in a far more uncertain position.

If you want the full architecture behind this — 503A vs. 503B facilities, the FDA’s category system, and how nominations move through review — we cover it in depth in our explainer on the compounded peptides and the 503A/503B landscape in 2026.

Which compounds are up — and the uses FDA reviewed

According to the FDA meeting notice, the committee will consider each substance (both free base and acetate forms) against a specific set of nominated uses. Those uses frame the science the committee is being asked to weigh:

Day 1 — July 23, 2026

• BPC-157 — reviewed for ulcerative colitis.
• KPV — reviewed for wound healing and inflammatory conditions.
• TB-500 — reviewed for wound healing.
• MOTS-c — reviewed for obesity and osteoporosis.

Day 2 — July 24, 2026

• DSIP (Emideltide) — reviewed for opioid withdrawal, chronic insomnia, and narcolepsy.
• Semax — reviewed for cerebral ischemia, migraine, and trigeminal neuralgia.
• Epitalon — reviewed for insomnia.

Two things worth noting. First, the nominated uses are often narrower than how these peptides are marketed — BPC-157 is being evaluated for ulcerative colitis, not the broad “healing and recovery” positioning it usually carries in the supplement world. Second, the presence of a compound on this agenda is not an endorsement of any of those uses; it is the starting point for a scientific debate. New to any of these names? Our peptide glossary has plain-English definitions.

What a 503A listing would — and would not — mean

It is easy to read “FDA committee reviews peptide” as either “it’s getting approved” or “it’s getting banned.” Both are wrong. Here is the more accurate framing:

A 503A listing would:

• Give traditional compounding pharmacies a clearer legal basis to compound the substance for an individual patient with a valid prescription.
• Reduce (not eliminate) the regulatory ambiguity that has surrounded these peptides.

A 503A listing would NOT:

• Make the peptide an FDA-approved drug. Compounding is a separate pathway from drug approval; compounded products are not FDA-approved for safety and efficacy.
• Authorize over-the-counter or “research-use-only” retail sale to consumers.
• Settle every question about a given use — the listing is substance-specific, and clinical judgment still applies.

Conversely, if the committee does not recommend a substance, that is a recommendation against adding it to the affirmative list — it is not automatically a prohibition, and FDA retains discretion over the final rule.

Realistic timeline: this is a step, not a verdict

A PCAC vote is one stage in a longer administrative process. The committee’s recommendation feeds into FDA’s rulemaking, which typically involves further review and formal notice-and-comment before any change to the Bulks List takes effect. Translation: do not expect a same-week change to what pharmacies can compound. Even a favorable recommendation would move through the agency on a timeline measured in months, not days.

The public also has a formal voice here. FDA established a docket for written comments through Regulations.gov, with comment deadlines tied to the meeting. That is the legitimate channel for practitioners, patients, and manufacturers to submit data — and it is worth watching, because the strength of the evidence submitted can shape the committee’s read.

What it means for patients and practitioners

For patients, the practical near-term reality does not change on July 24. If you currently work with a licensed clinician on a compounded peptide, this meeting does not alter that relationship overnight. What it may change over time is the clarity and availability of compliant, pharmacy-sourced options. If you are trying to find a licensed prescriber in the first place, our provider directory is the place to start.

For practitioners, the meeting is a signal to watch the evidence base closely. The uses FDA chose to evaluate are a tell about where the agency sees the most — and least — support. Clinicians who prescribe or advise on these compounds should track the committee’s reasoning, not just the yes/no outcome.

For the market, the outcome could sort the field. Peptides with a clear 503A pathway may consolidate around compliant compounding channels; those left off could face tighter sourcing. Either way, quality and verification matter more than ever — which is why we keep publishing vendor COAs and independent grading regardless of how the regulatory winds blow.

The honest bottom line

This is a genuinely important meeting — arguably the most important peptide-compounding event in years — but it is a committee review, not a final ruling. The responsible read is: know which compounds are up, know that the nominated uses are specific, know that a recommendation is not a law, and wait for the actual vote and FDA’s follow-through before drawing conclusions.

Not medical advice. This article is educational and informational only. Nothing here is a prescription, dosing recommendation, or medical guidance. Regulatory status does not equal safety or efficacy for any individual. Always consult a licensed healthcare provider.

We’ll update this story as PCAC posts its background materials (due no later than two business days before the meeting), during the live sessions, and after any votes. Check the dateline above for the latest revision.